Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Spinal Cord Compression Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (\> 18 years old) with histopathologically confirmed cancer~* Patients unable to ambulate independently due to paraparesis or paraplegia from malignant epidural spinal cord compression (categories 2, 3, 4 in Appendix B)~* Radiotherapy offered for treatment of cord compression using 2000cGy in 5 fractions~* Informed consent signed~* Females subjects must be post-menopausal or surgically incapable of childbearing potential, must be practicing an acceptable method of birth control (i.e., hormonal contraceptives, intrauterine device or barrier and spermicide)~Exclusion Criteria:~* Uncontrolled hypertension (systolic pressure \> 160 mmHg, diastolic \> 100 mmHg) or unstable cardiovascular disease~* Previous DVT/PE or arterial embolic event~* Patients with a Hb \> 120 g/L or Hct \> 40% (for both males \& females)~* Patients with potentially curable disease~* Patients with life expectancy \< 3 months~* Patients who have received RT that would overlap with the planned treatment field~* Contraindications for MRI scan~* Women who are pregnant, or who intend to become pregnant, or who are nursing~* Patients with known brain metastases; those with a primary diagnosis of melanoma will require confirmation by CT or MRI~* Patients with a history of poorly controlled seizure disorder~* Patients with a known hypersensitivity to mammalian cell-derived products or albumin~* Patients who cannot receive adequate antithrombotic treatment, who have a hypersensitivity to the active antithrombotic substance or any of the product's excipients~* Patients who have participated in another investigational device or drug trial(s), or is receiving other investigational agent(s) within the previous 30 days~* Patients requiring neurosurgical decompression for the malignant spinal cord compression

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).